Anavex Life Sciences Corp. · NASDAQ:AVXL
Anavex Life Sciences — Investor Presentation (January 2015)
29 slides from Anavex Life Sciences's investor presentation, Jan 6, 2015

Slide 1: Corporate Presentation
OTCQX: AVXL Corporate Presenta4on Christopher U. Missling, PhD President & CEO Winter 2015

Slide 2: Safe Harbor
Safe Harbor This presenta,on contains forward-‐looking statements made within the meaning of the Private Securi,es Li,ga,on Reform Act of 1995 by Anavex Life Sciences Corp. and its representa,ves. These statements can be iden,fied by introductory words such as ``expects,'' ``plans,'' ``intends,'' ``

Slide 3: Representative Sample of Over 3,000 Americans
Representa4ve Sample of Over 3,000 Americans … “… Majority say the scariest disabling condi,on of later life is Alzheimer’s …” 3

Slide 4: Alzheimer's Disease
Alzheimer’s Disease … “… Today every 67 seconds someone develops Alzheimer’s” ̶ The Alzheimer’s Associa1on 4

Slide 5: Anavex Overview
Anavex Overview ! Lead product, ANAVEX PLUS, currently in Phase 2a clinical trial in Alzheimer‘s disease (AD) -‐ ANAVEX PLUS is a “cocktail” of our proprietary compound, ANAVEX 2-‐73 and donepezil (Aricept®) -‐ ANAVEX 2-‐73 is an orally available small molecule with a clean Phase 1 data profile -

Slide 6: Rapidly Increasing Prevalence and Morbidity
Rapidly Increasing Prevalence and Morbidity Projected AD Changes in Number of Deaths Prevalence in the US (All Ages) Between 2000 and 2010 Aging is Strongest Predictor ! 40 million Americans are over the age of 65 ! 80 million Americans over 65 by 2040 Sources: Alzheimer’s Associa1on, ICAD, UC Davis

Slide 7: Alzheimer's is the Largest and Fastest Growing Therapeutic Area
Alzheimer’s is the Largest and Fastest Growing Therapeu4c Area ! More effec4ve and poten4ally disease-‐modifying treatments will create a mul4billion dollar product market opportunity $80bn $67.1bn $70bn $60bn Market Assuming $20,000 per year Potential $40bn treatment cost $30bn Assuming $100,000 pe

Slide 8: Alzheimer's: Complicated Cause with Tragic Outcome
Alzheimer‘s: Complicated Cause with Tragic Outcome ... Stages of Increased Alzheimer’s burden Loss of speech; locomo,on, Terminal consciousness; death Very Severe Full-‐,me care needed; ins,tu,onalized Can no longer care for self; incon,nent, depressed Severe Can no longer manage personal affairs; a

Slide 9: Alzheimer's Disease is Complicated
Alzheimer‘s Disease is Complicated ... ! Removing amyloid beta (A-‐beta) plaques in the brain may be too simplis4c to be effec4ve -‐ Recent disappointments of bapineuzumab (Pfizer), solanezumab (Eli Lilly), crenezumab (Roche) and gantenerumab (Roche) ! More likely: Free-‐floa4ng par4cles of A-‐beta

Slide 10: Chronic Stress of Aging: Misfolding of Proteins
Chronic Stress of Aging: Misfolding of Proteins … !People are living longer -‐ Age is strongest correla,on to develop AD !Chronic stress of aging in brain cells causes gradual accumula4on of damaged proteins causing misfolding of proteins -‐ Protein Misfolding creates a “Domino Effect” !ANAVEX PLUS

Slide 11: ANAVEX PLUS Reverses Cycle of Protein Misfolding
ANAVEX PLUS Reverses Cycle of Protein Misfolding Poten4al Mode of Ac4on for ANAVEX PLUS -‐ mixed muscarinic / Sig-‐1R agonist Ca2+ modula,on, reducing inflamma,on, mitochondrial dysfunc,on, and oxida,ve stress, while also reducing both A-‐beta and Tau ANAVEX PLUS ANAVEX PLUS ANAVEX PLUS Exposing m

Slide 12: ANAVEX PLUS Targets all Hallmarks of AD
ANAVEX PLUS Targets all Hallmarks of AD ! Primary effect of A-‐beta toxicity: auer staying in neurons for too long con,nued induc,on ANAVEX PLUS of cell stress ! Endogenous Sig-‐1R expressed to reduce cell stress level ! Chronic cell stress possibly causing Alzheimer’s disease (high correla,on with

Slide 13: Recent 3rd Party Publications on Sigma-1R Pathway: Additional Indications
Recent 3rd Party Publica4ons on Sigma-‐1R Pathway: Addi4onal Indica4ons ! Sigma-‐1 receptor agonist poten,ally disease-‐modifying in Parkinson's disease ! Cenci, A. et al., Brain, April 22, 2014, doi: 10.1093/brain/awu107 ! Sigma-‐1 receptor agonist extending survival in ALS (Lou Gehrig's diseas

Slide 14: Broad Pipeline In Alzheimer's, Oncology and Pain
Broad Pipeline In Alzheimer’s, Oncology and Pain PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ANAVEX PLUS ALZHEIMER’S ANAVEX 2-73 ALZHEIMER’S ALS EPILEPSY ANAVEX 3-71 (AF710B) ALZHEIMER’S PARKINSON’S ANAVEX 1-41 DEPRESSION STROKE PARKINSON’S ALZHEIMER’S ANAVEX 1079 CANCER (MELANOMA) ACUTE & NEUROPATHIC PAIN

Slide 15: ANAVEX 2-73 Significantly Improves Memory in Transgenic Alzheimer's Disease Model
ANAVEX 2-‐73 Significantly Improves Memory in Transgenic Alzheimer's Disease Model (Tg2576) P<0.01 ! 10 month-‐old Tg2576 and WT male mice administered p.o. (oral) with tap water or ANAVEX 2-‐73 (3 mg/kg/day); Auer 2 months, tested for place learning in the water-‐maze; N = 6-‐12 per group Prese

Slide 16: ANAVEX PLUS: Synergistic Memory Enhancing Effect with Donepezil
ANAVEX PLUS: Synergis4c Memory Enhancing Effect of ANAVEX 2-‐73 with Donepezil (Aricept®) Improved memory ! Short-‐term (YMT) and long-‐term (PAT) memory test. Only the data with lowest doses are shown (mg/kg ip) . 100% protec,on level represents control group (Sc.Ab/V) and 0% represents toxic gro

Slide 17: ANAVEX PLUS: Potential Symptomatic and Disease-Modifying Agent
ANAVEX PLUS: Poten4al Symptoma4c and Disease-‐ Modifying Agent ! ANAVEX PLUS Δ=2.8 Δ=2.5 -‐ Combina,on of ANAVEX 2-‐73 “plus” donepezil (Aricept®) -‐ Poten,al novel combina,on drug for Alzheimer’s ! ANAVEX 2-‐73 is poten4ally disease modifying -‐ Able to reverse memory and learning deficits and

Slide 18: ANAVEX PLUS Anticipated Cognition Response is >2x Higher than Donepezil Alone
ANAVEX PLUS An4cipated Cogni4on Response is >2x Higher than Donepezil (Aricept®) Alone ! Lower clinical trial risk since one compound (donepezil) already on the market ! General efficacy of donepezil (Aricept®) 2-‐3 points on the ADAS-‐Cog scale ! Early AD progression proceeds at a rate of 5.5 point

Slide 19: ANAVEX 2-73 / ANAVEX PLUS Efficient Clinical Trial Execution Plan
ANAVEX 2-‐73 / ANAVEX PLUS Efficient Clinical Trial Execu4on Plan ANAVEX2-‐73-‐001 Study: ! Phase 1 (oral) ! Single Ascending Dose (SAD) ! Healthy subjects Completed ! Study Completed ANAVEX2-‐73-‐002 Study: ! Phase 2a (oral) ! Mild-‐to-‐moderate AD pa,ents ! Adap,ve trial Underway – Topline Da

Slide 20: FDA Guidelines for Adaptive Trial Design
FDA Guidelines for Adap4ve Trial Design " Fewer pa,ents needed " Shorter dura,on required " More likely to demonstrate an effect of the drug (if one exists) " More informa,ve on the treatment’s effects " Broader and beMer dose-‐response informa,on and subgroup effects " Op,mize trial parameters for Ph

Slide 21: Integrated Phase 2a with Adaptive Trial Design
ANAVEX 2-‐73/ ANAVEX PLUS: Integrated Phase 2a with Adap4ve Trial Design Phase 2a Study ANAVEX 2-‐73 Dose A-‐E Mild-‐to-‐moderate ANAVEX 2-‐73 Dose A-‐E + Donepezil AD pa4ents Donepezil* No. of Pa4ents: ! 32 mild-‐to-‐moderate AD pa,ents No. of Sites: ! 7 sites Alloca4on: ! Randomized Dura4

Slide 22: ANAVEX 2-73 Completed Phase 1
ANAVEX 2-‐73 Completed Phase 1 ! Randomized, placebo-‐controlled single ascending dose study ! 22 healthy male volunteers ! Strong safety profile -‐ No serious adverse event was reported, no study discon,nua,on -‐ Only at highest doses, observed adverse events included moderate and reversible diz

Slide 23: Financial Summary
Financial Summary Symbol: AVXL Shares Outstanding*: 71.5 million 52-‐Week Stock Price Range: $0.15-‐$0.60 Cash @ 9/30/2014: $7.3 million Cash Burn 1: ~$100K/mo. corporate Cash Burn 2: ~$500K/mo. w/trials * Assuming all notes from March 2014 financing converted 23

Slide 24: Comparable Companies
Comparable Companies Market Development Capitaliza4on Phase Ra4onale ($ Millions) Avanir 3,200 Marketed Sigma 1 Receptor (AVNR) Prothena Protein 570 Phase 1/2 (PRTA) misfolding Prana Alzheimer's 92 Phase 2 (PRAN) Disease 24

Slide 25: 2015 Progress and Upcoming Milestones
2015 Progress and Upcoming Milestones # Secure cGMP manufacturing for drug candidate trial supplies – 3Q 2014 # Start Phase 2a study in 2014 Safety and exploratory efficacy # Phase 1 full data in Q4 2014 ☐ Report data from Phase 2a study by Q3 2015 ☐ Start Phase 2/3 study in 2015 Ongoing safety and effi

Slide 26: Strong Relevant Team Track Record
Strong Relevant Team Track Record Management and Directors Christopher U. Missling, PhD, MBA Tasos Zografidis, PhD Bernd Metzner, PhD Elliot Favus, MD Tom Skarpelos Scien4fic Advisory Board Abraham Fisher, PhD Jeffrey Cummings, MD Aisen, MD Paul Norman Relkin, MD, PhD Michael Gold, MD John Harrison, Ph

Slide 27: Anavex Overview
Anavex Overview ! Lead product, ANAVEX PLUS, currently in Phase 2a clinical trial in Alzheimer‘s disease (AD) -‐ ANAVEX PLUS is a “cocktail” of our proprietary compound, ANAVEX 2-‐73 and donepezil (Aricept®) -‐ ANAVEX 2-‐73 is an orally available small molecule with a clean Phase 1 data profile -

Slide 28: Every 67 seconds someone develops Alzheimer's
Alzheimer’s Disease … “… Every 67 seconds someone develops Alzheimer’s” ̶ The Alzheimer’s Associa1on … Anavex is working on a poten,al solu,on. 28

Slide 29: Contact Us
Contact Us Corporate Office: Anavex Life Sciences Corp. 51 West 52nd Street, 7th floor New York, NY 10019 USA Shareholder & Media Rela4ons: Toll-‐free: 1-‐866-‐505-‐2895 Outside North America: + 1 (416) 489-‐0092 Email: ir@anavex.com www.anavex.com OTCQX: AVXL 29
Source: Internet Archive copy of anavex.com
More decks from Anavex Life Sciences Corp.
Proxy Contest (September 2026)25 slides · September 2026
AD/PD 2026, Copenhagen27 slides · Mar 21, 2026
Investor Presentation (February 2026)37 slides · February 2026
Investor Presentation (January 2026)37 slides · January 2026
Technical Presentation (February 2022)24 slides · Feb 2, 2022
Investor Presentation (September 2021)43 slides · Sep 13, 2021